Time to response of one treatment
In many studies, researchers are interested in evaluating a treatment or line of treatment in terms of response time, that is, the time until a complete or partial response to the drug occurs.
Examples: In these studies, healthcare professionals record for each participant whether they experience: complete response (CR), partial response (PR) or progression of disease (PD), as well as the time (from the start of the study) in which they present the respective condition, and then evaluate the treatment or line of treatment, in terms of response time, i.e. the time until a complete or partial response to the treatment appears.
The problem
In many studies, researchers are interested in evaluating a treatment or line of treatment in terms of response time, that is, the time until a complete or partial response to the drug occurs. In these studies, healthcare professionals record for each participant whether they experience: complete response (CR), partial response (PR) or progression of disease (PD), as well as the time (from the start of the study) in which they present the respective condition, and then evaluate the treatment or line of treatment, in terms of response time, i.e. the time until a complete or partial response to the treatment appears.
The purpose
Indication of the effectiveness of the treatment in terms of response time, i.e. the time until a complete or partial response to the treatment occurs.
The solution
With the use of the appropriate statistical methodology (Kaplan Meier curve, Median survival time with the corresponding 95% Confidence Intervals, Life table analysis), the evaluation of the treatment or line of treatment will be carried out, in order for the user to be able to evaluate its degree of effectiveness in terms of response time, i.e. the time until a complete or partial response to the treatment occurs.
The benefit
Health professionals will be able to easily, quickly and without having any particular level of statistical knowledge, evaluate the effectiveness of a treatment or line of treatment they are interested in, in terms of response time, i.e. the time until a complete or partial response occurs in treatment.
Indicative presentation of the data needed
- The first column of the data file must contain the code of the patients receiving the treatment the user is interested in (e.g. Unique patient code). In case there is no patient code in the user's data file, then in the first column he should add a serial number.
- The second column should contain the information about the response of each participant (e.g. 0: Progression of the disease, 1: Complete/Partial response) after a certain period of time of administration of the therapeutic treatment (e.g. 6 months).
- The third column should contain the date each participant joined the study.
- The fourth should contain the date on which each participant had a complete or partial response to treatment, or the date of their last follow-up.
- The fifth column should contain the information about whether the participant showed a full/partial response or not.
Note: The columns that will contain the date should be in the format DD/MM/YYYY.
Table 1. Indicative table of input data from the application user
|
Patient Code |
Date of entry into the study |
Date of disease progression or death or date of last follow-up |
Full/Partial response |
|
1 |
01/10/2021 |
20/10/2021 |
Yes |
|
2 |
15/10/2021 |
01/11/2021 |
No |
|
3 |
05/10/2021 |
30/06/2022 |
No |
|
4 |
09/10/2021 |
25/04/2022 |
Yes |
|
5 |
18/10/2021 |
30/06/2022 |
No |
|
6 |
27/10/2021 |
22/03/2022 |
Yes |
System Prerequisites:
- Toolbox accepts xlsx or csv files.
- The two variables denoting the dates must not have missing data.
- The variable indicating the partial/complete response must not contain missing data.
Output:
After the data input by the user and after a short period for the automated analysis to be completed, a report of the results and the statistical methods used is extracted from the system.
Note: For any clarification you need regarding the content of the use case or any information related to the collection or validity of your data please contact us.
